

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C07D 401/04, 471/04, 487/04 A61K 31/505	A1	(11) International Publication Number: WO 86/ 05181 (43) International Publication Date: 12 September 1986 (12.09.86)
(21) International Application Number: PCT/US86/00368 (22) International Filing Date: 24 February 1986 (24.02.86) (31) Priority Application Number: 709,622 (32) Priority Date: 8 March 1985 (08.03.85) (33) Priority Country: US (71) Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY [US/US]; Princeton, NJ 08544 (US). (72) Inventors: TAYLOR, Edward, C. ; 288 Western Way, Princeton, NJ 08544 (US). BEARDSLEY, George, Peter ; Tonawanda Valley, Box 192, Essex, CT 06426 (US). HARRINGTON, Peter, J. ; 716 North Rogers Avenue #1, Endicott, NY 13760 (US). FLETCHER, Stephen, R. ; 11 Bowles Place, Woughton-On-The-Green, Milton Keynes, Buckinghamshire (GB).		(74) Agent: COLLINS, Bruce, M.; Mathews, Woodbridge, Goebel, Pugh & Collins, P.O. Box 112-M, Morristown, NJ 07960 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), SU. Published <i>With international search report.</i>
(54) Title: PYRIDO[2,3-d]PYRIMIDIN DERIVATIVES (57) Abstract 2,4-Diamino- and 2-amino-4-hydroxy- derivatives of N-(4-[2-(pyrido[2,3-d]pyrimidin-6-yl)alkyl]-benzoyl)-L-glutamic acids, and the corresponding 5,6,7,8- tetrahydro compounds are antineoplastic agents. The compounds are prepared by hydrolytic or hydrogenolytic removal of carboxylic acid protecting groups from the correspondingly protected glutamic acid derivatives. A typical embodiment is N-(4-[2-(2-amino-4-hydroxy-5,6,7,8,-tetrahydropyrido[2-3-d]pyrimidin-6-yl)-ethyl]benzoyl)-L-glutamic acid.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

-1-

Description

PYRIDO[2,3-d]PYRIMIDINE DERIVATIVESTechnical Field

5 The invention pertains to derivatives of N-(4-[2-(pyrido[2,3-d]pyrimidin-6-yl)alkyl]benzoyl)-L-glutamic acid, which derivatives are antineoplastic agents, and to their preparation and use.

Background Art

10 The folic acid antimetabolites aminopterin and amethopterin (also known as 10-methylaminopterin or methotrexate) are antineoplastic agents. These compounds inhibit enzymatic conversions involving metabolic derivatives of folic acid. Amethopterin, for example, inhibits dihydrofolate reductase, an enzyme necessary
15 for the regeneration of tetrahydrofolate from the dihydrofolate which is formed during the conversion of 2-deoxyuridylate to thymidylate by the enzyme thymidylate synthetase.

20 Other derivatives of folic acid and aminopterin have been synthesized and tested as anti-metabolites. Among these are various "deaza" compounds in which a methylene or methylenedioxy group occupies a position in the molecule normally occupied by an imino or nitrilo group, respectively. These derivatives have
25 varying degrees of antimetabolic activity. 10-Deazaaminopterin is highly active (Sirotak et al., Cancer Treat. Rep., 1978, 62, 1047) whereas 10-deazafolic acid shows no significant activity (Struck et al., J. Med. Chem., 1971, 14, 693). 5-Deazafolic acid is only weakly
30 cytotoxic whereas 5-deazaaminopterin has activity similar to that of amethopterin (Taylor et al., J. Org. Chem., 1983, 48, 4852). 8,10-Dideazafolic acid is only marginally effective as a dihydrofolate reductase inhibitor (De Graw et al., "Chemistry and Biology of


-2-

Pteridines", Elsevier, 1979, 229) while 5,8,10-trideaza-folic acid also shows only marginal activity against mouse L1210 leukemia (Oatis et al., J. Med. Chem., 1977, 20, 1393). 8,10-Dideazaaminopterin is reported to be active (U.S. Patent No. 4,460,591) and 5,8,10-trideaza-aminopterin exhibits activity against mouse L1210 leukemia (Yan et al., J. Heterocycl. Chem., 1979, 16, 541).

Disclosure of Invention

The invention pertains to

(ia) pyrido[2,3-d]pyrimidines of the formula:




IA

wherein R¹ is amino or hydroxy; and

R³ is hydrogen, methyl, or ethyl;

the configuration about the carbon atom designated * being L;

(ib) 5,6,7,8-tetrahydropyrido[2,3-d]-pyrimidines of the formula:



IB

-3-

wherein R^1 is amino or hydroxy; and

R^3 is hydrogen, methyl, or ethyl;


the configuration about the carbon atom designated * being L;

- 5 (ii) the tautomeric forms thereof; and
(iii) the pharmaceutically acceptable alkali metal, alkaline earth metal, non-toxic metal, ammonium, and substituted ammonium salts thereof.


10 The invention also pertains to methods for the preparation of such compounds, to intermediates useful in those preparations, and to methods and compositions for the use of such compounds in combatting neoplastic growth.

Modes For Carrying Out The Invention

15 The compounds of the invention are derivatives of the pyrido[2,3-d]pyrimidine heterocyclic ring which is numbered as follows:



25 The compounds of Formulas IA and IB in which R^1 is hydroxy exist in tautomeric equilibrium with the corresponding 3,4-dihydro-4-oxo compounds.



For convenience, the 4-hydroxy form is depicted and the corresponding nomenclature is used throughout this specification, it being understood that

-4-

in each case such includes the tautomeric 3,4-dihydro-4-keto form.

The absolute configuration about the carbon atom designated * in the glutamic acid chain is L, being the same absolute configuration as that about the corresponding alpha carbon atom in alanine.

When R³ is other than hydrogen, a second chiral center is present, thereby producing d,L- and l,L-diastereoisomers. These can be separated mechanically, as by chromatography. In the case of the 5,6,7,8-tetrahydro compounds of Formula IB, the carbon atom in the 6-position of the pyrido[2,3-d]pyrimidine ring system also is a chiral center, leading to d,L- and l,L-diastereoisomers if R³ is hydrogen and to d,l,L-, d,d,L-, l,l,L-, and l,d,L-diastereoisomers if R³ is other than hydrogen. All of the above forms, which can be separated as described above, are within the scope of the invention.

The invention includes the pharmaceutically acceptable alkali metal, alkaline earth metal, non-toxic metal, ammonium, and substituted ammonium salts, such as for example the sodium, potassium, lithium, calcium, magnesium, aluminum, zinc, ammonium, trimethylammonium, triethylammonium, triethanolammonium, pyridinium, substituted pyridinium, and the like.

The compounds of this invention have an effect on one or more enzymes which utilize folic acid, and in particular metabolic derivatives of folic acid, as a substrate. The following compounds are representative:

Compound No. 1. N-(4-[2-(2,4-diaminopyrido[2,3-d]-pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

Compound No. 2. N-(4-[2-(2-amino-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

-5-

Compound No. 3. N-(4-[2-(2,4-diamino-5,6,7,8-tetra-
hydropyrido[2,3-d]pyrimidin-6-yl)-
ethyl]benzoyl)-L-glutamic acid.

5 Compound No. 4. N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-
tetrahydropyrido[2,3-d]pyrimidin-6-yl)-
ethyl]benzoyl)-L-glutamic acid.

Table 1

Inhibition of Dihydrofolate Reductase (DHFR)
(Kaufman et al., "Methods in Enzymology",
10 Jacobs and Wilcheck, Eds., Academic Press:
New York, 1974, pp 272-281)

	Compound	IC ₅₀ ^M
	1	4.3x10 ⁻⁸
15	2	4.9x10 ⁻⁵
	3	7.1x10 ⁻⁸
	4	5.6x10 ⁻⁴

Table 2

Inhibition of Thymidylate Synthetase
20 (Wahba et al., J. Biol. Chem., 1961, 236, p 611)

	Compound	IC ₅₀ ^M
	1	9.2x10 ⁻⁵
	2	7.7x10 ⁻⁵
25	3	9.2x10 ⁻⁴
	4	>1x10 ⁻³

-6-

Table 3

Substrate for Folate Polyglutamate Synthetase

Incubation with partially purified mouse liver
 5 FPGS [specific activity = $1.2 \text{ nmol h}^{-1} (\text{mg}^{-1} \text{ of protein})$]
 for one hour at 37°C ; full saturation curves obtained
 for duplicate assays at 6 concentrations - see Moran et
 al., Anal. Biochem., 1984, 146, 326.

	Compound	Rel [*] K_m	Rel [*] V_{max}
10	1	0.86 ± 0.11	0.35 ± 0.02
	2	0.68 ± 0.14	0.90 ± 0.10
	3	0.23 ± 0.01	1.61 ± 0.05
	4	0.05 ± 0.02	1.24 ± 0.10
	FH_4	$0.05 \pm 0.01^{\dagger}$	$1.31 \pm 0.07^{\dagger}$

15 * Relative to folic acid.

† Published data, see Moran et al., Biochemistry,
 1984, 23, 4580.

Table 4

Inhibition of L1210 murine leukemic cells in
 20 tissue culture - see Foley et al., Biochem. Pharmacol.,
 1967, 16, 658.

	Compound	$\text{IC}_{50}^{\text{M}}$
	1	1.7×10^{-8}
25	2	$>10^{-4}$
	3	3.3×10^{-9}
	4	5.9×10^{-8}

Table 5

Increase in life span (ILS) in mice (BDF_1)
 30 following peritoneal injection of 10^{-5} L1210 leukemia
cells. Compounds administered intraperitoneally for 9
 days at indicated dosage.

-7-

	<u>Compound</u>	<u>Dose (mg/kg)</u>	<u>% ILS</u>
	1	4	130
	3	1	111
	4	2	27
5		4	35
		8	59
		12	63


N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydro-
 pyrido[2,3-d]pyrimidin-6-yl)-ethyl]benzoyl)-L-glutamic
 10 acid in particular is a unique antimetabolite. While
 maintaining good activity against L-1210 leukemia which
 is comparable to methotrexate, the compound is a weak
 inhibitor of dihydrofolate reductase, indicating prob-
 able activity against the folate-related enzyme targets
 15 other than DHFR. This conclusion is supported by its
 activity against methotrexate-resistant cells.

Table 6
Effect on Methotrexate-Resistant L-1210 Leukemia

	<u>Compound</u>	<u>Dose (mg/kg)</u>	<u>Mean Increased Life span in days</u>
20	control	-	0
	Methotrexate	2	0
	4	2	+8
25	4	4	+11
	4	8	+17
	4	12	+25

The compounds can be prepared by hydrolysis or
 hydrogenolysis of a glutamic acid derivative of the
 30 formula:

-8-




5

II

in which R^1 and R^3 are as previously defined;
 R^4 is


10



15

or

20



R^5 and R^6 are the same or different carboxylic acid protecting group; and


R^7 is hydrogen or an amino acid protecting group.

The hydrolysis is conducted at normal temperatures utilizing aqueous acid or base, such as for example, an aqueous alkali metal hydroxide, optionally in the presence of a water miscible organic solvent such as methanol, ethanol, tetrahydrofuran, dimethylformamide, and the like, or an acid, as for example trifluoroacetic acid. When base is used, the product is initially formed as the dicationic glutamate salt and can be readily precipitated by adjustment of pH, as

-9-

through acidification with, for example, acetic acid. The resulting products generally are high melting crystalline or microcrystalline solids.


The glutamic acid intermediate of Formula II can be obtained by hydrogenating a pyrido[2,3-d]-pyrimidine compound of the formula:



III

15 wherein R^1 , R^3 , R^5 , R^6 and R^7 are as previously defined. The hydrogenation can be performed at from 50 to 100 psi in an inert solvent and in the presence of a suitable catalyst such as the noble metals or metal
20 oxides such as palladium or platinum oxide, optionally on a support such as carbon or calcium carbonate; e.g. Pd/C, Pd/CaCO₃, PtO₂.

The 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidinyl intermediate of Formula II in which R^4 is




can be produced by independent hydrogenation of the corresponding compound of Formula II wherein R^4 is

35

-10-


5



Alternatively, a 5,6,7,8-tetrahydropyrido-
 10 [2,3-d]pyrimidinyl intermediate of Formula II can be
 formed directly in the hydrogenation of the pyrido-
 [2,3-d]pyrimidine intermediate of Formula III through
 the use of more vigorous conditions, such as increasing
 the hydrogenation time, increasing the pressure and/or
 15 raising the temperature.

The intermediate of Formula III can be pre-
 pared in several ways. In one embodiment, a benzoic
 acid derivative

20




25

IV

is coupled with a protected glutamic acid derivative of
 the formula

30




V

utilizing conventional condensation techniques for
 forming peptide bonds, such as activation of the
 35 carboxylic acid through formation of the mixed
 anhydride, treatment with DCC, or use of diphenylchloro-
 phosphonate.


-11-

Alternatively an aldehyde of the formula



VI


10 (see Taylor et al., J. Org. Chem., 1983, 48, 4852) can be coupled with a Wittig reagent of the formula



VII

20 (see Yan, J. Het. Chem., 1979, 16, 541) in the presence of sodium hydride, or another strong non-nucleophilic base, in a solvent such as N-methylpyrrolidone or dimethylformamide. The reverse reaction also can be employed, namely the reaction of a Wittig reagent of the

25




VIII

35 with a N-(4-formyl- or 4-alkanoylbenzoyl)-L-glutamic acid in which the carboxylic acid groups are protected.


-12-

The benzoic acid derivative of Formula IV can be prepared by cyclization of a 4-[1-(2-substituted 3-cyano-pyridin-5-yl)alk-1-en-2-yl]benzoate of the formula



IX

in which R^8 is amino or 4-nitrophenylthio, with guanidine in t-butanol and an equimolar amount of an alkali metal t-butoxide such as sodium or potassium t-butoxide. Generally, the benzoate ester is a t-butyl ester. Other alkoxide-alcohol combinations can also be used for the guanidine cyclization reaction, but care should be taken to minimize transesterification. The product of this cyclization is a 4-[1-(2,4-diamino-pyrido[2,3-d]pyrimidin-6-yl)alk-en-2-yl]benzoate of the formula




X

The benzoate of Formula X can be hydrolyzed with acid such as aqueous formic acid to yield the corresponding benzoic acid derivative of Formula IV in which R^1 is amino and R^7 is hydrogen. The 2,4-diamino compounds of Formula IV are converted to the corresponding 2-amino-4-hydroxy compound through treatment with base. It is desirable first to protect the 2-amino

-13-

group through conversion to the acetamido group. Hence treatment with acetic anhydride in the presence of a hydrogen acceptor such as 4-dimethylaminopyridine results in acylation of the 2-amino group and formation of a benzoic acid mixed anhydride, the latter being hydrolyzed with base to regenerate the free benzoic acid derivative of Formula IV. Treatment with base such as 1 N sodium hydroxide then generates the corresponding 4-hydroxy compound.

Intermediate IX also can be prepared through use of a Wittig reagent. Thus [2-(4-nitrophenylthio)-3-cyanopyridin-5-ylmethyl]triphenylmethylphosphonium bromide can be obtained according to Taylor et al., J. Org. Chem., 1983, 48, 4852 by condensation of 2-methyl-3-ethoxyacrolein and alpha-cyanothioacetamide to yield 3-cyano-5-methyl-2(1H)pyridinethione, treatment of the product with 4-nitrofluorobenzene to yield 2-(4-nitrophenylthio)-3-cyano-5-methylpyridine, bromination with N-bromosuccinimide to yield 2-(4-nitrophenylthio)-3-cyano-5-bromomethylpyridine, and addition of triphenylphosphine. This compound is then coupled with a compound of the formula



in which R^3 is as previously defined.

Amino and carboxylic acid protecting groups are described for example by Greene in "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981, and McOmie in "Protective Groups in Organic Chemistry", Plenum Press, 1983.

The compounds of Formula IA and IB can be used, alone or in combination, to treat neoplasms which in the past have been treated with methotrexate, including choriocarcinoma, leukemia, adenocarcinoma of the

-14-

female breast, epidermid cancers of the head and neck, squamous or small-cell lung cancer, and various lympho-sarcomas. The compounds can also be used to treat mycosis fungoides and psoriasis which are responsive to methotrexate.

The compounds may be administered either orally or preferably parenterally, alone or in combination with other anti-neoplastic agents, steroids, etc., to a mammal suffering from neoplasm and in need of treatment. Parenteral routes of administration include intramuscular, intrathecal, intravenous or intra-arterial. In general, the drug is administered in much the same fashion as methotrexate, but because of its different mode of action N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]-benzoyl)-L-glutamic acid can be administered in higher dosages than those usually employed with methotrexate. Leucovorin rescue is not needed. Dosage regimens must be titrated to the particular neoplasm, the condition of the patient, and the response but generally doses will be from about 10 to about 100 mg/day for 5-10 days or single daily administration of 250-500 mg, repeated periodically; e.g. every 14 days. Oral dosage forms include tablets and capsules containing from 1-10 mg of drug per unit dosage. Isotonic saline solutions containing 20-100 mg/ml can be used for parenteral administration.

The following examples will serve to further illustrate the invention. In the NMR data, "s" denotes singlet, "d" denotes doublet, "t" denotes triplet, "q" denotes quartet, "m" denotes multiplet, and "br" denotes a broad peak.

-15-

Example 1

[3-Cyano-2-(4-nitrophenylthio)-5-pyridinylmethyl]triphenylphosphonium Bromide:

A. A mixture of 60.00 g (0.221 mol) of
5 3-cyano-2-(4-nitrophenylthio)-5-methylpyridine, 39.37 g
(0.221 mol) of N-bromosuccinimide, 3.0 g of benzoyl
peroxide and 60 mL of benzene was refluxed for 16 hours
while being irradiated with a 275-W sunlamp. The sol-
vent was removed under reduced pressure and the residue
10 was shaken with a mixture of 1 L of water and 1 L of
methylene chloride. The organic layer was separated,
washed with 1 L of water, dried over anhydrous magnesium
sulfate, and filtered. Removal of the solvent by evap-
oration under reduced pressure yielded 3-cyano-2-
15 (4-nitrophenylthio)-5-bromomethylpyridine which can be
used in the following step without further purification.

B. The solid obtained in Part A was stirred
at room temperature with a solution of 58.01 g (0.221
mol) of triphenylphosphine in 500 mL of benzene. Fil-
20 tration of the reaction mixture gave 77.63 g of
[3-cyano-2-(4-nitrophenylthio)-5-pyridinylmethyl]tri-
phenylphosphonium bromide.

Stirring of the mother liquor at room tempera-
ture for 6 hours afforded an additional 5.67 g, (total
25 yield 83.30 g, 62%). Recrystallization from acetonitrile
gave [3-cyano-2-(4-nitrophenylthio)-5-pyridinylmethyl]-
triphenylphosphonium bromide as light yellow crystals,
mp < 200°C, with resolidification, mp 253-256°C with
dec.

30 C. Alternatively, 3-cyano-2-(4-nitrophenyl-
thio)-5-bromomethylpyridine is allowed to react in
tetrahydrofuran with tri-(n-butyl)phosphine for ten

-16-

hours. Following the addition of ether, the solid which forms is collected by filtration and washed with 1:1 tetrahydrofuran:ether to yield [3-cyano-2-(4-nitro-phenylthio)pyridin-5-ylmethyl]-tri-(n-butyl)phosphonium bromide as a white solid; mp 175-176°C; NMR (CDCl₃, 80 MHz) δ 0.85-2.63(m, 27H), 4.76(d, 2H, J=15.4 Hz), 7.74(d, 2H, J=9.0 Hz), 8.26(d, 2H, J=9.0 Hz), 8.55 (brs, 1H), 8.79 (brs, 1H); IR (KBr) 2950, 2860, 2220, 1595, 1575, 1515, 1390, 1340, 1075 and 845 cm⁻¹; HRMS 471.2116(M⁺-HBr), Calc'd. for C₂₅H₃₄N₃O₂ PS471.2109.

Example 2

3-Cyano-2-(4-nitrophenylthio)-5-[2-(4-ethoxycarbonylphenyl)ethenyl]pyridine.

A. A mixture of 4.544 g (7.42 mmol) of [3-cyano-2-(4-nitrophenylthio)-5-pyridinylmethyl]tri-phenylphosphonium bromide, 0.751 g (7.42 mmol) of tri-ethylamine and 50 mL of chloroform was stirred at room temperature for 15 minutes and 1.322 g (7.42 mmol) of 4-ethoxycarbonylbenzaldehyde then were added. After stirring at room temperature for 96 hours, 100 mL of water were added, the mixture was filtered, and the organic layer was separated and washed twice with 100 mL portions of water, dried and filtered. Evaporation of the filtrate under reduced pressure gave a residue which was chromatographed on silica gel. Unreacted aldehyde was eluted with 2:1 petroleum ether:benzene, while the title compound, alternatively named as 2-(4-nitrophenylthio)-3-cyano-5-(4-ethoxycarbonylstyryl)pyridine, was eluted with benzene. Evaporation of the benzene eluate gave 2.82 g (88%) of 3-cyano-2-(4-nitrophenylthio)-5-[2-(4-ethoxycarbonylphenyl)ethenyl]pyridine as a light yellow solid. The product turns from a solid to a gum below 100°C and then to a clear liquid between 180 and 220°C; NMR (Me₂SO-d₆) δ 1.34 (t, 3H, J=6.3 Hz), 4.32

-17-

(q, 2H, J=6.3 Hz), 6.73 (d, 1H, J=13 Hz), 6.99 (d, 1H, J=13 Hz), 7.27 (d, 2H, J=9Hz), 7.74, 7.85, 7.94 (dd, 2H, 2H), 8.26, 8.31 (dd, 2H, 1H), 8.38 (d, 1H, J=1.8 Hz); IR (KBr) 2220, 1707, 1605, 1597, 1575, 1512, 1344, 1295-1277, 1174 cm^{-1} .

Anal.: Calc'd. for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}_4\text{S}$: C, 64.08; H, 3.97; N, 9.74; S, 7.43. Found: C, 63.82; H, 4.01; N, 9.51; S, 7.38.

B. 3-Cyano-2-(4-nitrophenylthio)-5-[2-(4-tert-butoxycarbonylphenyl)ethenyl]pyridine was prepared in 81% yield by the above method utilizing however 4-(tert-butoxycarbonyl)benzaldehyde in place of 4-ethoxycarbonylbenzaldehyde; mp indefinite (cis-trans mixture); NMR (CDCl_3) δ 1.62 (s, 9H), 6.43 (d, 1H, J=13 Hz), 6.90 (d, 1H, J=13 Hz), 7.24 (d, 2H, J=9 Hz), 7.69 (d, 2H, J=8.1 Hz), 7.76 (d, 1H, J=2.7 Hz), 7.92 (d, 2H, J=8.1 Hz), 8.22 (d, 2H, J=9 Hz), 8.34 (d, 1H, J=2.7 Hz); IR (KBr) 2220, 1707, 1600, 1577, 1518, 1341, 1290, 1163 cm^{-1} .

Anal.: Calc'd. for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$: C, 65.35; H, 4.61; N, 9.14; S, 6.98. Found: C, 65.28; H, 4.68; N, 9.20; S, 6.93.

In a similar fashion by substituting a 4-alkoxycarbonylacetophenone or a 4-alkoxycarbonylpropiophenone for 4-ethoxycarbonylbenzaldehyde, there is respectively obtained the corresponding 3-cyano-2-(4-nitrophenylthio)-5-[2-(4-alkoxycarbonylphenyl)prop-1-enyl]pyridine and 3-cyano-2-(4-nitrophenylthio)-5-[2-(4-alkoxycarbonylphenyl)but-1-enyl]pyridine compounds. This can be exemplified as follows:

To a solution of 18.89 g of [3-cyano-2-(4-nitrophenylthio)-5-pyridinylmethyl]-tri-(n-butyl)phos-

-18-

phonium bromide in 150 mL of dry methylene chloride were added in several small portions 5.36 mL of 1,5-diazabicyclo[5.4.0]undec-5-ene. After stirring the reaction mixture under a nitrogen atmosphere for 15 minutes, 7.53 g of 4-(t-butoxycarbonyl)acetophenone (alternatively named as tert-butyl 4-acetylbenzoate) were added. The mixture was heated under reflux for 72 hours, cooled to room temperature, and extracted with a saturated sodium chloride solution. The extracts were dried over anhydrous sodium sulfate and then chromatographed on flash silica gel using methylene chloride as the eluent. The eluate was concentrated under reduced pressure and the residue was triturated with ether. The resulting solid was collected by filtration to yield 5.64 g (35%) of trans-3-cyano-2-[(4-nitrophenylthio)]-5-[2-(4-tert-butoxycarbonylphenyl)prop-1-enyl]pyridine as a pale yellowish solid: mp 180-181.5°C (benzene-ether); NMR (CDCl₃, 250 MHz): d 1.61 (s, 9H), 2.29 (d, 3H, J=1.23 Hz), 6.70 (brs, 1H), 7.52 (d, 1H, J=8.62 Hz), 7.74 (d, 1H, J=8.84 Hz), 7.92 (d, 1H, J=2.09 Hz), 8.00 (d, 1H, J=8.62 Hz), 8.27 (d, 1H, J=8.84 Hz), 8.53 (d, 1H, J=2.09 Hz); IR (KBr) 3060, 2970, 2220, 1695, 1595, 1515, 1425, 1380, 1365, 1340, 1290, 1160, 1110, 1010 and 840 cm⁻¹.

Anal. Calc'd. for C₂₆H₂₃N₃O₄S: C, 65.94; H, 4.90; N, 8.87; S, 6.77. Found: C, 66.88; H, 4.64; N, 8.51; S, 6.77.

Concentration of the filtrate under reduced pressure and trituration of the residue, followed by filtration and washing with ether, yielded 2.08 g (13%) of the cis-3-cyano-2-(4-nitrophenylthio)-5-[2-(4-tert-butoxycarbonylphenyl)prop-1-enyl]pyridine as a pale yellowish solid, mp 126-127°C (ethyl acetate-hexane); NMR (CDCl₃, 250 MHz) d 1.60 (s, 9H), 2.25 (d, 3H, J=1.41 Hz), 6.39 (brs), 7.18 (d, 1H, J=8.28 Hz), 7.41 (d, 1H, J=2.22 Hz), 7.63 (d, 1H, J=8.91 Hz), 7.95 (d, 1H, J=8.28

-19-

Hz), 8.09 (d, 1H, J=2.22 Hz), 8.23 (d, 1H, J=8.91 Hz);
IR (KBr) 3110, 2970, 2225, 1720, 1520, 1345, 1165, 1105,
920 and 840 cm^{-1} .

Anal. Calc'd. for $\text{C}_{26}\text{H}_{23}\text{N}_3\text{O}_4\text{S}$: C, 65.94; H,
5 4.90; N, 8.87; S, 6.77. Found: C, 65.92; H, 4.81; N,
8.62; S, 656.

The 4-(t-butoxycarbonyl)acetophenone utilized
in the foregoing procedure can be prepared as follows:

To a suspension of 1.64 g of 4-acetylbenzoic
10 acid in 30 mL of dry benzene were added 3.0 mL of
freshly distilled thionyl chloride. The mixture was
heated under reflux for 5 hours. The reaction mixture
was cooled to room temperature and the solvent was re-
moved under reduced pressure. The resulting residue was
15 dissolved in 5 mL of dry methylene chloride and the
solution was added to a mixture of 1.11 g of dry tert-
butanol and 1.42 g of dry pyridine. After stirring the
reaction mixture under a nitrogen atmosphere for 15
hours, the mixture was diluted with methylene chloride
20 and extracted with water. The organic solution was
dried over anhydrous sodium sulfate and the solvent was
removed under reduced pressure. The residue was chro-
matographed on a column of silica gel using a 20% ethyl
acetate-hexane mixture as the eluent. The major frac-
25 tion isolated from the column contained 2.01 g (91%) of
4-(t-butoxycarbonyl)acetophenone as a white solid: mp
56.5-57.5°C; NMR (CDCl_3 , 80 MHz) δ 1.61 (s, 9H), 2.63 (s,
3H, 7.95 (d, 2H, J=9.0 Hz), 8.09 (d, 2H, J=9.0 Hz); IR
(KBr) 2980, 2930, 1720, 1680, 1400, 1365, 1295, 1250,
30 1165, 1100, 845, 760 and 690 cm^{-1} .

Alternatively, 4-(t-butoxycarbonyl)aceto-
phenone can be isolated by distillation under reduced
pressure, bp 90-100°C/0.1 mm. Analogously 4-(t-butoxy-

-20-

carbonyl)propiophenone is prepared and converted to 3-cyano-2-(4-nitrophenylthio)-5-[2-(4-tert-butoxycarbonylphenyl)but-1-enyl]pyridine.

Example 3

5 2-Amino-3-cyano-5-[2-(4-ethoxycarbonylphenyl)-ethenyl]pyridine.

A suspension of 2.00 g (4.64 mmol) of 3-cyano-2-(4-nitrophenylthio)-5-[2-(4-ethoxycarbonylphenyl)-ethenyl]pyridine, 1.553 g (6.95 mmol) of cupric bromide, 10 and 50 mL of liquid ammonia was stirred in a pressure tube at room temperature for 13 days. Evaporation of the ammonia afforded a dark residue which was chromatographed over magnesium silicate using methylene chloride as eluant. The eluate was removed by evaporation under 15 reduced pressure and the residue chromatographed on silica gel. Unreacted starting material was eluted with benzene while 0.87 g (64%) of the product, which can be alternatively named as 2-amino-3-cyano-5-(4-ethoxycarbonylstyryl)pyridine, was eluted with ethyl acetate 20 and obtained by evaporation of the ethyl acetate solvent as a light yellow solid, mp 135-141.5°C; NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.39 (t, 3H, J=6.3Hz), 4.38 (q, 2H, J=6.3 Hz), 6.67 (m, 2H), 7.10 (br, 2H), 7.45 (d, 2H, J=9 Hz), 7.71 (d, 1H, J=3.6 Hz), 7.97 (d, 2H, J=9 Hz), 8.11 (d, 1H, J=3.6 Hz); IR (KBr) 3155, 2218, 1715, 1650-1645, 1593, 25 1491, 1277, 1100 cm^{-1} .

Anal. Calc'd. for $\text{C}_{17}\text{H}_{15}\text{H}_3\text{O}_2$: C, 69.61; H, 5.16; N, 14.33. Found: C, 69.37; H, 5.25; N, 14.22.

By substituting an equivalent amount of 3-cyano-2-(4-nitrophenylthio)-5-[2-(4-tert-butoxycarbonylphenyl)ethenyl]pyridine in the foregoing procedure there 30 is obtained 2-amino-3-cyano-5-[2-(4-tert-butoxycarbonyl-

-21-

phenyl)ethenyl]pyridine, which can be alternatively named as 2-amino-3-cyano-5-(4-*t*-butoxycarbonylstyryl)-pyridine; yield 1.14 g (84%) of light yellow crystals, mp 190-195°C; NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.57 (s, 9H), 5 6.57-6.60 (m, 2H), 7.00 (br, 2H), 7.35 (d, 2H, $J=8.1$ Hz), 7.65 (d, 1H, $J=2.7$ Hz), 7.84 (d, 2H, $J=8.1$ Hz), 8.00 (d, 1H, $J=2.7$ Hz); IR (KBr) 3460, 3360, 2215, 1707, 1623, 1480, 1300, 1287, 1158 cm^{-1} .

Anal. Calc'd. for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2$: C, 71.00; H, 10 5.96; N, 13.07. Found: C, 70.83; H, 6.03; N, 12.83.

Example 4

2,4-Diamino-6-[2-(4-*tert*-butoxycarbonyl-phenyl)ethenyl]pyrido[2,3-*d*]pyrimidine.

To a solution of 4.54 mmol of guanidine as the 15 free base (obtained from 0.433 g (4.54 mmol) of guanidine hydrochloride and 0.114 g of sodium in 25 mL of dry *tert*-butanol) was added 1.325 g (4.12 mmol) of 2-amino-3-cyano-5-[2-(4-*tert*-butoxyphenyl)ethenyl]pyridine. The deep red suspension was heated at reflux under dry 20 nitrogen for 8 hours. The reaction mixture was cooled to room temperature and filtered. The precipitate was washed successively with water, acetone, and ether and was then dried under reduced pressure to yield 0.911 g (61%) of the title compound, which can be alternatively 25 named as 2,4-diamino-6-(4-*tert*-butoxycarbonylstyryl)-5-deazapteridine, as a light yellow solid, mp >350°C; NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.55 (s, 9H), 6.42 (br, 2H), 6.73 (m, 2H), 7.30-8.00 (br, 2H), 7.35 (d, 2H, $J=9$ Hz), 7.81 (d, 2H, $J=9$ Hz), 8.34 (m, 2H); IR (KBr) 3320-3300, 3200- 30 3140, 2970, 1718, 1626, 1610-1600, 1550, 1450-1445, 1288, 1167, 812 cm^{-1} .

-22-

Anal.: Calc'd. for $C_{20}H_{21}N_5O_2$: C, 66.10; H, 5.82; N, 19.27. Found: C, 65.88; H, 5.86; N, 18.98.

Example 5

2,4-Diamino-6-[2-(4-carboxyphenyl)ethenyl]-
pyrido[2,3-d]pyrimidine.

A. A solution of 1.27 g of 2,4-diamino-6-[2-(4-tert-butoxycarbonylphenyl)ethenyl]pyrido[2,3-d]pyrimidine and 10 mL 88% formic acid was stirred at room temperature. A yellow solid started to form after about 12 hours and after 4 days of stirring, the reaction mixture was filtered. The collected solid was washed well successively with water, methanol, and acetone and was then dried under reduced pressure to give 0.85 g (79%) of the title compound, which can be alternatively named as 2,4-diamino-6-(4-carboxystyryl)-5-deazapteridine, mp $>300^{\circ}\text{C}$.

B. Alternatively, 0.48 g of 2,4-diamino-6-[2-(4-tert-butoxycarbonylphenyl)ethenyl]pyrido[2,3-d]pyrimidine was added to a saturated solution of hydrogen chloride in 20 mL of nitromethane at 0° . The reaction mixture quickly became viscous and turned a deep yellow color and after a few minutes of stirring, a granular solid formed. After 1 hour of stirring, 50 mL of ether were added and the precipitate was collected by filtration. The collected solid was dissolved in 50 mL of 10% aqueous sodium carbonate. Acidification with acetic acid then resulted in the separation of a yellow solid which was collected by filtration and dried under reduced pressure; yield 0.31 g (92%) of 2,4-diamino-6-[2-(4-carboxyphenyl)ethenyl]pyrido[2,3-d]pyrimidine; NMR ($\text{Me}_2\text{SO}-d_6$) δ 6.75 (s, 2H), 7.35, 7.85 (AB q, 4H, $J=9$ Hz), 8.38 (s, 2H); IR (Nujol) 3400-2300, 3380, 3150, 1700, 1650, 1630, 1590 cm^{-1} .

-23-

Example 6

2,4-Diamino-6-[2-(4-tert-butoxycarbonyl-phenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine.

To a suspension containing 1.93 g of guanidine hydrochloride in 75 mL of dry tert-butanol at 50°C under a nitrogen atmosphere was added 0.50 g of sodium metal. After all the sodium was dissolved, 7.97 g of trans-3-cyano-2-(4-nitrophenylthio)-5-[2-(4-tert-butoxycarbonyl-phenyl)prop-1-enyl]pyridine was added. The mixture was heated under reflux for 3 hours, cooled to room temperature, diluted with ether, and filtered. The solid was washed with water and acetone, and then dried under reduced pressure to yield 4.66 g (73%) of the title compound as a pale yellowish solid; mp >300°C; NMR (DMSO-d₆, 80 MHz) δ 1.56(s, 9H), 2.23 and 2.29 (brs, 3H), 6.57 and 6.99 (brs, 1H), 7.25-8.73 (m, 8H); IR (KBr) 3340, 3130, 1710, 1640, 1608, 1540, 1450, 1365, 1340, 1290, 1165, 1110, 840 and 810 cm⁻¹.

Example 7

2,4-Diamino-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine.

A suspension containing 4.58 g of 2,4-diamino-6-[2-(4-tert-butoxycarbonylphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine in 200 mL of a saturated solution of hydrogen chloride gas in nitromethane was stirred at 0°C for 1 hour, and then at room temperature for 3 hours. After dilution with ether, the reaction mixture was filtered and the collected solid was washed successively with water, methanol, and acetone and then dried under reduced pressure to give 3.90 g (100%) of 2,4-diamino-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine. NMR (DMSO-d₆, 80 MHz) δ 2.31 (brs, 3H), 6.77 and 7.07

-24-

(brs, 1H), 7.74 (d, 2H, J=8.5Hz), 7.98 (d, 2H, J=8.5 Hz), 8.26, (d, 1H, J=2.0 Hz), 8.74 d, 1H, J=2.0Hz).

Example 8

2-Amino-4-hydroxy-6-[2-(4-carboxyphenyl)-
ethenyl]pyrido[2,3-d]pyrimidine.

A. A suspension of 1.0 g of 2,4-diamino-6-[2-(4-carboxyphenyl)ethenyl]pyrido[2,3-d]pyrimidine in 30 mL of 1 N aqueous sodium hydroxide was heated under reflux under nitrogen for 3 hours. The resulting homogeneous orange solution was cooled to room temperature, acidified with 6 mL of glacial acetic acid, and the resulting yellow precipitate collected by filtration. The filter cake was washed successively with water, methanol, acetone and ether and was then dried under reduced pressure to give 0.88 g (88%) of the title compound, which can be alternatively named as either 6-[2-(4-carboxyphenyl)ethenyl]-5-deazapterin or 6-(4-carboxystyryl)-5-deazapterin, as a microcrystalline yellow powder, mp >250°C; NMR (TFA-d₁ delta 6.8, 7.25 (AB q, 2H, J=12 Hz), 7.45, 8.2 (AB q, 4H, J=9 Hz), 8.55 (s, 1H), 8.85 (s, 1H); IR (Nujol) 3500-2500 (br), 1670, 1625, 1600 cm⁻¹.

B. In a similar fashion, 2,4-diamino-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine is converted to 2-amino-4-hydroxy-6-[2-(4-carboxyphenyl)-prop-1-enyl]pyrido[2,3-d]pyrimidine, mp >250°C; NMR (DMSO-d₆, 80 MHz) d 2.28 and 2.30 (brs, 3H), 6.77 and 7.06 (brs, 1H), 7.72 (d, 2H, J=8.5Hz), 7.97 (d, 2H, J=8.5 Hz), 8.27 (d, 1H, J=2.0 Hz), 8.72 (d, 1H, J=2.0 Hz).

-25-

Example 9

2-Acetamido-4-hydroxy-6-[2-(4-acetoxycarbonyl-phenyl)ethenyl]pyrido[2,3-d]pyrimidine.

A suspension of 0.88 g of 2-amino-4-hydroxy-6-
5 [2-(4-carboxyphenyl)ethenyl]pyrido[2,3-d]pyrimidine in
20 mL of acetic anhydride containing 0.05 g of 4-di-
methylaminopyridine was heated under nitrogen at 120°C
for 3 hours. The reaction mixture was cooled to room
temperature. Fifty milliliters of ether were added and
10 the resulting yellow solid was collected by filtration
to yield 0.95 g (84%) of the title compound; mp >300°C;
IR (Nujol) 3350, 3150, 1800, 1670, 1600 cm⁻¹.

Example 10

2-Acetamido-4-hydroxy-6-[2-(4-carboxyphenyl)-
15 ethenyl]pyrido[2,3-d]pyrimidine.

To a suspension of 0.95 g of 2-acetamido-4-
hydroxy-6-[2-(4-acetoxycarbonylphenyl)ethenyl]pyrido-
[2,3-d]pyrimidine in 50 mL of water was added 1 N
aqueous sodium hydroxide until a homogenous solution was
20 obtained. Acidification with acetic acid resulted in
the formation of a yellow precipitate which was collec-
ted by filtration. The filter cake was washed sequen-
tially with water, methanol, acetone and ether. The
residual solid was recrystallized from DMF to give 0.65
25 g (77%) of the title compound, which can be alterna-
tively named as 2-acetamido-6-(4-carboxystyryl)-5-
deaza-4(3H)-pteridinone, as a microcrystalline yellow
solid, mp >300°C; NMR (TFA-d₁) delta 2.5 (s, 3H), 6.85,
7.32 (AB q, 2H, J=12 Hz), 7.45, 8.18 (AB q, 4H, J=9Hz),
30 8.65 (s, 1H), 9.02 (s, 1H); IR (Nujol) 3300-2200 (br),
1685, 1655, 1630, 1600, 1565 cm⁻¹. MS: Calc'd. for
C₁₈H₁₄N₄O₄: 350. Found: m/e 350 (base), 308.

-26-

Example 11

2-Acetamido-4-hydroxy-6-[2-(4-carboxyphenyl)-prop-1-enyl]pyrido[2,3-d]pyrimidine.

By subjecting 2-amino-4-hydroxy-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine to the procedures of Examples 9 and 10, there was obtained 2-acetamido-4-hydroxy-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine, mp >250°C; in an overall yield of 45%; NMR (CF₃CO₂D/DMSO-d₆, 80 MHz) δ 2.15 (s, 3H), 2.22 (s, 3H), 6.72 (brs, 1H), 7.45 (d, 2H, J=8.4 Hz), 7.92 (d, 2H, J=8.4 Hz), 8.65 (d, 1H, J=2.0 Hz), 8.98 (d, 1H, J=2.0 Hz).

Example 12

Diethyl N-(4-[2-(2,4-diaminopyrido[2,3-d]-pyrimidin-6-yl)ethenyl]benzoyl)-L-glutamate.

A. To a solution of 1.0 g (0.0033 mol) of 2,4-diamino-6-[2-(4-carboxyphenyl)ethenyl]pyrido[2,3-d]pyrimidine and 1 g of N-methylmorpholine in 120 mL of N-methylpyrrolidone cooled to 5°C is added, in a drop-wise fashion, 1.4 g (0.0048 mol) of diphenyl chlorophosphonate. The reaction mixture was stirred for 1 hour and an additional 0.5 mL of N-methylmorpholine were added, followed by 1.1 g (0.0048 mol) of diethyl L-glutamate hydrochloride. The reaction mixture was stirred overnight at room temperature and the solvent then was removed under reduced pressure. The residual solid was washed with 50 mL of dry ether, triturated with 100 mL of 1 N aqueous sodium hydroxide, and the resulting suspension centrifuged. The collected solid was dissolved in 200 mL of 3:1 chloroform:methanol and filtered through Florisil. The filtrate was evaporated to a small volume; 10 g of Florisil were added, and the

-27-

resulting impregnated Florisil added to the top of a Florisil column which was then eluted sequentially with ethyl acetate followed by ethyl acetate containing increasing quantities of methanol (9:1, 3:1, and 1:1).
5 The title compound was collected in the 3:1 and 1:1 fractions. Evaporation of the combined eluates gave a glassy material which was triturated with ether and then collected by filtration; yield 0.41 g (26%), mp 183-185°C; NMR ($\text{Me}_2\text{SO}-d_6/\text{TFA}$) δ 1.25-1.45 (overlapping t, 6H, $J=7$ Hz), 2.25-2.50 (m, 2H), 2.5-2.8 (m, 2H), 4.05-4.45 (overlapping q, 4H, $J=7$ Hz), 4.8-5.0 (m, 1H), 6.8, 7.2 (AB q, 2H, $J=16$ Hz), 7.4, 7.85 (AB q, 4H, $J=9$ Hz), 8.6 (s, 1H), 9.05 (s, 1H); IR (Nujol) 3500-3000, 1730, 1635, 1605 cm^{-1} . MS: Calc'd. for $\text{C}_{25}\text{H}_{28}\text{N}_6\text{O}_5$: 492. Found: m/e 492, 290, 94, 84.

B. Alternatively the triphenylphosphonium salt [prepared from triphenylphosphine and diethyl 4-bromomethylbenzoylglutamate (7.86 g, 0.012 mol) following the method of Yan et al., J. Het. Chem., 16, 541 (1979)] was added portionwise to a slurry of 0.4 g (0.01 mol) of sodium hydride (60% suspension in oil) in 70 mL of dry N-methylpyrrolidone over a period of 10 minutes. The resulting red reaction mixture was stirred at room temperature under nitrogen for 1 hour. To this
25 in situ Wittig reagent were added 2.27 g (0.012 mol) of 2,4-diamino-6-formylpyrido[2,3-d]pyrimidine [prepared by the method of Baldwin et al., J. Org. Chem. 43, 2529 (1978)]. The resulting slurry was stirred at room temperature under nitrogen for 3 weeks. The solvent was then evaporated under reduced pressure, the residual
30 solid triturated with benzene to remove triphenylphosphine oxide, and the purified solid collected by centrifugation. The solid was resuspended in water, filtered, and the collected solid dissolved in 200 mL of
35 chloroform:methanol (1:2). Florisil (10 g) was added, the mixture was evaporated to dryness, and the impreg-

-28-

nated Florisil residue applied to the top of a Florisil column which was then eluted with ethyl acetate containing increasing quantities of methanol (from 9:1 to 1:1). Fractions containing eluted material were combined and were shown to contain two products (TLC). The mixture was chromatographed again on silica gel utilizing chloroform and methanol as eluants. The initial fraction was a phosphorane and the product was thereafter eluted and obtained in a yield of 1.7 g (34.5%) in form identical to that obtained in part A of this example.

C. Following the procedure of part A of this example but utilizing 2,4-diamino-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine, there can be obtained diethyl N-(4-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)prop-1-enyl]benzoyl)-L-glutamate.

Alternatively, 2.2 g (0.0074 mol) of di-tert-butyl L-glutamate hydrochloride were allowed to react with 1.5 g (0.0049 mol) of 2,4-diamino-6-[2-(4-carboxyphenyl)ethenyl]pyrido[2,3-d]pyrimidine, to yield di-tert-butyl N-(4-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)ethenyl]benzoyl)-L-glutamate in a yield of 1.3 g (48%), mp >300°C. NMR (CDCl₃/CD₃OD) delta 1.47, 1.52 (2s, 18H), 2.0-2.6 (m, 4H), 4.5-7.0 (m, 1H), 6.8 (br, s, 2H), 7.35, 7.78 (AB q, 4H, J=9 Hz), 8.38 (s, 1H), 8.5 (s, 1H); IR (Nujol) 3350, 3180, 1725, 1640, 1605 cm⁻¹. MS: Calc'd.: for C₂₉H₃₆N₆O₅: 548. Found: m/e 548, 446, 290.

Example 13

Diethyl N-(4-[2-(2-acetamido-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)ethenyl]benzoyl)-L-glutamate.

-29-

To an ice cold solution of 1.5 g (0.0043 mol) of 2-acetamido-4-hydroxy-6-[2-(4-carboxyphenyl)ethenyl]-pyrido[2,3-d]pyrimidine in 40 mL of N-methylpyrrolidone containing 1.4 mL of N-methylmorpholine was added 1.72 g (0.0064 mol) of phenyl N-phenylphosphoramidochloridate in a single portion. The resulting mixture was stirred at 0°C for 30 minutes. Diethyl L-glutamate hydrochloride (1.53 g, 0.0064 mol) was then added and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure and the residual solid triturated with 50 mL of 1 N aqueous sodium carbonate. The mixture was filtered and the collected solid dissolved in 20 mL of chloroform. The chloroform solution was dried over anhydrous magnesium sulfate and filtered. The filtrate was evaporated to dryness and chromatographed on silica gel. Elution with chloroform:methanol (95:5) gave 1.52 g (66%) of the title compound, which may be alternatively named as diethyl 2-acetyl-5,10-dideaza-9,10-didehydrofolate, mp >250°C; NMR (CDCl₃Me₂SO-d₆) delta 1.15-1.45 (2t, 6H, J=6 Hz), 2.0-2.65 (m, 4H), 2.3 (s, 3H), 4.0-4.35 (2q, 4H, J=6 Hz), 4.5-4.75 (m, 1H), 6.7, 6.9 (AB q, 2H, J=15 Hz), 7.33, 7.84 (AB q, 4H, J=9 Hz), 8.25-8.38 (m, 2H), 8.62 (d, 1H, J=2Hz), 11.5-12.5 (br, 2H); IR (Nujol) 3320, 3150, 1730, 1680, 1630, 1600 cm⁻¹.

Anal.: Calc'd. for C₂₇H₂₉N₅O₇: C, 60.56; H, 5.42; N, 13.08. Found: C, 60.26; H, 5.45; N, 12.84.

Example 14

Diethyl N-(4-[2-(2-acetamido-4-hydroxypyrido-
[2,3-d]pyrimidin-6-yl)prop-1-enyl]benzoyl)-L-glutamate.

To a solution of 0.2 g of 2-acetamido-4-hydroxy-6-[2-(4-carboxyphenyl)prop-1-enyl]pyrido[2,3-d]pyrimidine in 50 mL of N-methylpyrrolidinone containing

-30-

0.18 g of N-methylmorpholine was added 0.22 g of phenyl N-phenylphosphoramidochloridate in a single portion. After stirring the mixture at room temperature for 1 hour, 0.20 g of diethyl L-glutamate was added. The reaction mixture was stirred overnight, the solvent was removed under reduced pressure and the residue was triturated with chloroform. The mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was subjected to preparative thin layer chromatography on silica gel using a 5% methanol in chloroform mixture as the eluent. This gave 74.6 mg (25%) of the title compound as a pale yellowish solid; NMR (CDCl₃, 250 MHz) δ 1.22 (t, 3H, J=7.1 Hz), 1.30 (t, 3H J=7.1 Hz), 2.11-2.57 (m, 10H), 4.14 (q, 2H, J=7.1 Hz), 4.24 (q, 2H, J=7.1 Hz), 4.75-4.83 (m, 1H), 6.86 (brs, 1H), 7.18 (brs, 1H), 7.57 (d, 2H, J=8.42 Hz), 7.84 (d, 2H, J=8.42 Hz), 8.50 (d, 1H, J=2.01 Hz), 8.96 (brs, 1H), 10.34 (brs, 1H).

Example 15

Diethyl N-(4-[2-(2,4-diaminopyrido[2,3-d]-pyrimidin-6-yl)ethyl]benzoyl)-L-glutamate.

A solution of 0.9 g of diethyl N-(4-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)ethenyl]benzoyl)-L-glutamate in 40 mL of trifluoroacetic acid was hydrogenated under 55 psi of hydrogen for 24 hours using 2.5 g of Pd/C as catalyst. The catalyst was removed by filtration through celite and the filtrate was evaporated. The residual solid was triturated with 30 mL of 2 N aqueous sodium carbonate, followed by a water wash. The resulting solid was purified by column chromatography on silica gel. Elution with chloroform:methanol (95:5) afforded a small amount (0.2 g) of the tetrahydro derivative while subsequent elution with chloroform:methanol (1:4) gave 0.52 g (58%) of the title compound, which can

-31-

be alternatively named as diethyl N-(4-[2-(2,4-diamino-5-deaza-6-pteridyl)ethyl]benzoyl)-L-glutamate; mp >200°C; NMR (Me₂SO-d₆) delta 1.1-1.3 (2t, 6H, J=7 Hz) 1.8-2.6 (m, 4H), 3.05 (s, 4H), 3.1-3.8 (br, 5H), 3.9-4.2 (2q, 4H, J=7 Hz), 4.3-4.5 (m, 1H), 7.35, 7.85 (AB q, 4H, J=9 Hz), 8.6 (br, s, 2H): IR (Nujol) 3320, 3150, 1650 cm⁻¹.

Example 16

Diethyl N-(4-[2-(2,4-diamino-5,6,7,8-tetra-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamate.

10 By repeating the procedure of Example 15 but continuing the hydrogenation for 72 hours, the title compound, which can be alternatively named as diethyl N-(4-[2-(2,4-diamino-5-deaza-5,6,7,8-tetrahydro-6-pteridyl)ethyl]-benzoyl)-L-glutamate, was obtained as a
15 crude product which was chromatographed on silica gel using chloroform:methanol (95:5) to give 0.42 g (31%) of the product as a colorless microcrystalline solid; mp >250°C; NMR (Me₂SO-d₆) delta 1.6, 1.8 (2t, 6H, J=6 Hz), 1.4-3.8 (m, 13H), 4.1 (2q, 4H, J=6 Hz), 4.3-4.6 (m, 1H),
20 6.8 (s, 2H), 7.35, 7.85 (AB q, 4H, J=9Hz), 8.7 (d, 1H, J=9 Hz); IR (Nujol) 3350, 3150, 1730, 1630 cm⁻¹. MS: Calc'd. for C₂₅H₃₄N₆O₅: 498. Found: m/e 498, 425, 178, 165 (base), 150.

Example 17

25 Diethyl N-(4-[2-(2-acetamido-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]-benzoyl)-L-glutamate.

A solution of diethyl N-(4-[2-(2-acetamido-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)ethenyl]benzoyl)-
30 L-glutamate in 30 mL of trifluoroacetic acid was hydrogenated at 55 psi of hydrogen in the presence of 1.0 g

-32-

of 5% Pd/C at room temperature for 14 hours. The catalyst was removed by filtration, the filtrate evaporated under reduced pressure, and the residual solid partitioned between 100 mL of chloroform and 50 ml of 2N aqueous sodium carbonate. The organic phase was separated, dried over anhydrous magnesium sulfate, and the solvent removed by evaporation to give a gum which was chromatographed on silica gel. Elution with chloroform:methanol (97:3) gave 0.25 g (56%) of diethyl N-(4-[2-(2-acetamido-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamate; mp 215-217°C; NMR (CDCl₃) delta 1.25, 1.35 (2t, 6H, J=6 Hz), 2.1-2.5 (m, 4H), 2.55 (s, 3H), 3.1 (s, 4H), 4.15, 4.25 (2q, 4H, J=6 Hz), 4.6-4.96 (m, 1H), 7.05 (s, 1H), 7.25, 7.75 (AB q, 4H, J=9 Hz), 8.35 (d, 1H, J=3 Hz), 8.77 (d, 1H, J=3 Hz); IR (Nujol) 3200, 3150, 1725, 1675, 1630, 1605 cm⁻¹. Anal.: Calc'd. for C₂₇H₃₁N₅O₇: C, 60.32; H, 5.81; N, 13.03. Found: C, 59.98; H, 6.03; N, 12.92).

Further elution with 95:5 chloroform:methanol yielded 0.08 g (18%) of the title compound, which can be alternatively named as diethyl 2-acetyl-5,10-dideaza-5,6,7,8-tetrahydrofolate; mp >200°C; NMR (CDCl₃/Me₂SO-d₆) delta 1.24, 1.28 (2t, 6H, J=6 Hz), 1.5-3.3 (m, 13H), 2.18 (s, 3H), 4.1, 4.18 (2a, 4H, J=6 Hz), 4.4-4.7 (m, 1H), 6.2 (s, 1H), 7.28, 7.85 (AB q, 4H, J=9 Hz), 8.4 (d, 1H, J=8 Hz); IR (Nujol) 3320, 3250, 1730, 1630, 1575 cm⁻¹. Anal.: Calc'd. for C₂₇H₃₅N₅O₇: C, 59.87; H, 6.51; N, 12.93. Found: C, 59.66; H, 6.71; N, 12.77.

Example 18

Diethyl N-(4-[2-(2-acetamido-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)propyl]benzoyl)-L-glutamate.

A solution of 84.4 mg of diethyl N-(4-[2-(2-acetamido-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)-

-33-

prop-1-enyl]benzoyl)-L-glutamate in 30 mL of trifluoroacetic acid was hydrogenated at 55 psi of hydrogen in the presence of 0.42 g of 5% Pd/C at room temperature for 24 hours. The catalyst was removed by filtration and the filtrate was evaporated under reduced pressure. The resulting residue was taken up in chloroform and was extracted with a saturated sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was then subjected to thin layer chromatography using a 5% methanol:chloroform mixture as the eluent. After elution of a first fraction, there was obtained 19.6 mg of the title compound, NMR (CDCl₃, 250 MHz), δ 1.20-1.33 (m, overlapping methyls, 9H), 2.45-3.36 (m, 15H), 4.11 (q, 2H, J=7.14 Hz), 4.23 (q, 2H, J=7.10 Hz), 4.89 (m, 1H), 5.44 (brs, 1H), 7.24 (d, 2H, J=7.54 Hz), 7.72 (d, 2H, J=7.54 Hz), 9.77 (brs, 1H), 11.26 (brs, 1H).

Example 19

N-(4-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

A solution of 0.38 g of diethyl N-(4-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamate in 50 mL of methanol containing 4.6 mL of 0.5 N aqueous sodium hydroxide was stirred at room temperature for 72 hours. Acetic acid (5 mL) was added, and the resulting white precipitate collected by filtration. The filter cake was washed well with water, methanol, and ether and was dried under reduced pressure to yield 0.15 g (44%) of the title compound, which can be alternatively named as 5,10-dideazaaminopterin; mp >250°C; NMR (TFA-d₁) δ 2.2-2.7 (m, 2H), 2.28; 2.7-2.95 (m, 2H), 5.0-5.2 (m, 1H), 7.35 and 7.85 (AB q, 4H, J=9 Hz), 8.7 (s, 1H), 9.1 (s, 1H).

-34-

Example 20

N-(4-[2-(2,4-diamino-5,6,7,8-tetrahydropyrido-
[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

Following the procedure of Example 19,
5 hydrolysis of 0.35 g of diethyl N-(4-[2-(2,4-diamino-
5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]-
benzoyl)-L-glutamate yielded 0.13 g (42%) of the title
compound, which can be alternatively named as 5,10-
dideaza-5,6,7,8-tetrahydroaminopterin, mp >250°C.

10

Example 21

N-(4-[2-(2-amino-4-hydroxypyrido[2,3-d]-
pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

A homogeneous solution of 0.175 of diethyl
N-(4-[2-(2-acetamido-4-hydroxypyrido[2,3-d]pyrimidin-
15 6-yl)ethyl]benzoyl)-L-glutamate in 50 mL of methanol
containing 3 mL of 1N aqueous sodium hydroxide was
stirred at room temperature for 72 hours. Addition of 2
mL of acetic acid followed by centrifugation gave 0.125
g (86%) of the title compound, which can be alterna-
20 tively named as 5,10-dideazafolic acid, as a micro-
crystalline colorless solid, mp >200°C; NMR (TFA-d₁)
delta 2.3-2.7 (m, 2H), 2.7-3.0 (m, 2H), 3.25 (s, 5H),
4.9-5.25 (m, 1H), 7.35, 7.85 (AB q, 4H, J=9 Hz), 8.50
(s, 1H), 8.90 (s, 1H).

25

Example 22

N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetra-
hydropyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-
L-glutamic acid.

-35-

Diethyl N-(4-[2-(2-acetamido-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamate was hydrolyzed in an analogous fashion to that described in Example 21 to yield the title compound, which can be alternatively named as 5,10-dideaza-5,6,7,8-tetrahydrofolic acid, in 87% yield; mp >250°C, NMR (TFA) delta 1.7-3.9 (m, 13H), 5.0-5.25 (m, 1H), 7.45, 7.85 (AB q, 4H, J=9 Hz).

Similarly obtained from diethyl N-(4-[2-(2-acetamido-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)ethenyl]benzoyl)-L-glutamate was N-(4-[2-(2-amino-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)ethenyl]benzoyl)-L-glutamic acid, mp >200°C.

Example 23

N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)propyl]benzoyl)-L-glutamic acid.

A homogeneous solution of 17.5 mg of diethyl N-(4-[2-(2-acetamido-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)propyl]benzoyl)-L-glutamate in 2 mL of methanolic sodium hydroxide solution was allowed to stand at room temperature for 72 hours. Most of the solvent was then removed under reduced pressure and the mixture was diluted with water and acidified with acetic acid. The precipitate was collected by filtration, washed with water, and dried under reduced pressure (0.1 mm) for 48 hours to give 9.7 mg (67%) of the title compound, which may be alternatively named as 5,10-dideaza-10-methyl-5,6,7,8-tetrahydrofolic acid. mp >250°C, NMR delta 0.87-0.88 (brs, 1H each), 1-2.8 (m, 11H), 3.13 (m, 1H), 4.59 (m, 1H), 6.96 (d, 2H, J=9 Hz), 7.34 (d, 2H, J=9 Hz).

-36-

Analogously N-(4-[1-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)but-2-yl]-benzoyl)-L-glutamic acid and N-(4-[1-(2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)but-2-yl]-benzoyl)-L-glutamic acid are prepared.

Example 24

In typical models, the indicated tumor cells were implanted subcutaneously in the axillary region of mice. Following intraperitoneal administration of the first compound of Example 22, the length and width of the control tumor (receiving only saline) are measured at the indicated time and compared to those of animals receiving the test compound to calculate percentage of inhibition.

15		<u>% INHIBITION</u>				
		<u>Dose mg/kg</u>				
	<u>Tumor System</u>	<u>25</u>	<u>50</u>	<u>100</u>	<u>200</u>	<u>Days of Treatment</u>
20	6C3HED Lymphosarcoma	91	100	100	100	8
	B-16	98	99	100	100	5
	C3H Mammary Adenocarcinoma	86	100	100	100	10
25	Lewis Lung Carcinoma	58	77	94	100	10
	M-5 Ovarian Carcinoma	12	31	54	80	10*
	Madison Lung	54	72	87	90	10
30	X5563 Plasma Cell Myeloma	100	100	100	100†	10


* 5 Day Delay

† Toxic

WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of:

(ia) pyrido[2,3-d]pyrimidines of the formula:




wherein:

R^1 is amino or hydroxy;

R^3 is hydrogen, methyl, or ethyl; and

15 the configuration about the carbon atom designated * is L;

(ib) 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidines of the formula:



wherein:

R^1 is amino or hydroxy;

R^3 is hydrogen, methyl, or ethyl; and


30 the configuration about the carbon atom designated * is L;

(ii) the tautomeric forms thereof; and

(iii) the pharmaceutically acceptable alkali metal, alkaline earth, non-toxic metal, ammonium, and substituted ammonium salts thereof.

-38-

2. A compound according to claim 1 which is a 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine of the formula:



10 wherein R^1 is amino or hydroxy; and R^3 is hydrogen, methyl, or ethyl.

15 3. A compound according to claim 2 wherein R^3 is hydrogen.

4. A compound according to claim 3 wherein R^1 is hydroxy.

20 5. The compound according to claim 1 which is N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido-[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

25 6. The compound according to claim 1 which is N-(4-[1-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido-[2,3-d]pyrimidin-6-yl)prop-2-yl]benzoyl)-L-glutamic acid.

30 7. The compound according to claim 1 which is N-(4-[1-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido-[2,3-d]pyrimidin-6-yl)but-2-yl]benzoyl)-L-glutamic acid.

8. A compound according to claim 2 wherein R^1 is amino.

35 9. The compound according to claim 1 which is N-(4-[2-(2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]-

-39-

pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

10. The compound according to claim 1 which is N-(4-[1-(2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]-
5 pyrimidin-6-yl)prop-2-yl]benzoyl)-L-glutamic acid.

11. The compound according to claim 1 which is N-(4-[1-(2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]-
pyrimidin-6-yl)but-2-yl]benzoyl)-L-glutamic acid.

10

12. The compound according to claim 1 which is N-(4-[2-(2-amino-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)-
ethyl]benzoyl)-L-glutamic acid.

15

13. The compound according to claim 1 which is N-(4-[1-(2-amino-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)-
prop-2-yl]benzoyl)-L-glutamic acid.

20

14. The compound according to claim 1 which is N-(4-[1-(2-amino-4-hydroxypyrido[2,3-d]pyrimidin-6-yl)-
but-2-yl]benzoyl)-L-glutamic acid.

25

15. The method of combating neoplastic growth in a mammal which comprises administering to the mammal
in a single or multiple dose regimen an effective amount
of a compound according to claim 1.

30

16. The method of combating neoplastic growth in a mammal which comprises administering to the mammal
in a single or multiple dose regimen an effective amount
of a compound according to claim 5.

35


17. A pharmaceutical composition for combating neoplastic growth in a mammal which comprises an amount
of a compound according to claim 1 which upon admini-
stration to the mammal in a single or multiple dose
regimen is effective to combat said growth, in combina-

-40-

tion with a pharmaceutically acceptable carrier.

18. A pharmaceutical composition for combating neoplastic growth in a mammal which comprises an amount of a compound according to claim 5 which upon administration to the mammal in a single or multiple dose regimen is effective to combat said growth, in combination with a pharmaceutically acceptable carrier.

19. The process for the preparation of a compound according to claim 1 which comprises subjecting a glutamic acid derivative of the formula:




in which


R^1 is as therein defined;

R^3 is hydrogen, methyl or ethyl;

R^4 is



or




R^5 and R^6 are the same or different carboxylic acid protecting group; and

-41-

R^7 is hydrogen or an amino protecting group, to hydrolysis or hydrogenolysis.

20. A compound of the formula:



wherein

R^1 is amino or hydroxy;

R^3 is hydrogen, methyl, or ethyl; and

Z is hydroxy, alkoxy, or

15 $-\text{NH}-\text{C}^*\text{H}(\text{COOX})-\text{CH}_2\text{CH}_2\text{COOX}$ in which X is hydrogen or alkyl and the configuration about the carbon atom designated * is L.

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US86/00368

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
INT. Cl. 4 C07D 401/04, 471/04, 48704, A61K 31/505		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	544/279, 514/258	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
CHEMICAL ABSTRACTS VOLS. 1-101 UNDER PYRIDO [3,2-d] PYRIMIDINE, PYRIDO[2,3-d] PYRIMIDINE-L-GLUTAMIC ACID DERIVATIVES		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	US,A, 4,431,805 Published 14, February 1984 Temple et al.	1-18
A	US,A, 4,432,981 Published 21, February 1984 Leshner et al.	1-14
X	US,A, 4,460,591 Published 17, July 1984 DeGraw et al.	1-20
A,P	US,A, 4,512,992 Published 23, April 1985 Duch et al.	1-14
Y,P	US,A, 4,526,964 Published 02, July 1985 Temple et al.	1-20
X,P	US,A, 4,532,241 Published 30, July 1985 DeGraw et al.	1-20
Y,P	US,A, 4,536,575 Published 20, August 1985 Temple et al.	1-20
<p>¹⁶ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²		Date of Mailing of this International Search Report ³
02 April 1986		21 APR 1986
International Searching Authority ¹		Signature of Authorized Officer ¹⁰
ISA/US		S. Kepner <i>[Signature]</i>

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
X,P	WO,A 85/02844 Published 04, July 1985 DeGraw et al.	1-20
X	Journal of Organic Chemistry, Volume 48, No. 25, 1983, E.C. Taylor et al., 'Synthesis and Biological Activity of L-5- Deazafolic Acid and L-5-Deazaaminopterin: Synthetic Strategies to 5-Deazapteridines, pp. 4852-4860.	1-20
A	A. Goodman et al., eds., 'The Pharmaco- logical Basis of Therapeutics, Sixth edi- tion, MacMillan Publishing Co. (New York), pp. 1272-1277.	1-14
Y	Chemical Abstracts, Volume 81, 1975 (Columbus, OH), J.I. DeGraw et al., 'Antimicrobial Activity of 8-Deazafolic Acid', abstract no. 86420u, J. Med. Chem. 1974, 17(4), 470-1 (Eng.).	1-14, 17-18
A	Chemical Abstracts, Volume 88, 1978 (Columbus, OH), J. I. DeGraw et al., 'Synthesis of 2-amino-4-hydroxy-1,3,5- triazanaphthalenes', abstract no. 22807n, J. Heterocycl. Chem. 1976, 13(3), 439-41 (Eng.).	1-14
Y	Chemical Abstracts, Volume 93, 1980 (Columbus, OH), A. Srinivasan et al., 'Pyridopyrimidines. 11. Synthesis of 5- deaza-5-oxoaminopterin and related com- pound, abstract no. 150215h, J. Org. Chem. 1980, 45(19), 3746-8 (Eng.).	1-14
A	Chemical Abstracts, Volume 94, 1981, (Columbus, OH), A. Srinivasan et al., 'Pyridopyrimidines 12. Synthesis of 8- deaza analogs of aminopterin and folic acid', abstract no. 2088145, J. Org. Chem. 1981, 46(9), 1777-81 (Eng.).	1-14
Y	Chemical Abstracts, Volume 95, 1981, (Columbus, OH), C. Temple et al., 'New Synthesis of N-[4-[[[(2-amino-4(3H)-oxo- pyrido[3,2-3]pyrimidin-6-yl)methyl]amino] benzoyl]-L-glutamic acid (8-deazafolic acid) and the preparation of some 5,6,7,8- tetrahydro derivatives', abstract no. 125980n, J. Med. Chem. 1981, 24(10), 1254-8 (Eng.).	1-14

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	Chemical Abstracts, Volume 96, 1982 (Columbus, OH), C. Temple et al. 'Pyrido[2,3-d]Pyrimidines. The Synthesis of the 5-deaza analogs of aminopterin, methotrexate, folic acid, and N ¹⁰ -methylfolic acid, abstract no. 85954u, J. Org. Chem. 1982, 47(5), 761-4 (Eng.).	1-14
A	Chemical Abstracts, Volume 97, 1982 (Columbus, OH), A. Srinivasan et al., 'Synthesis of an 8-deaza analog of the intermediate in the thymidylate synthetase reaction, abstract no. 110382m, Tetrahedron Lett. 1982, 23(14), 1431-4 (Eng.).	1-14
A	Chemical Abstracts, Volume 98, 1983 (Columbus, OH), P.J. Harrington, 'Synthetic approaches to 5-deaza and 5,10 dideaza folic acid analogs', abstract no. 179838c, Diss. Abstr. Int. B 1982, 43(1), 138-9.	1-14, 20
Y	Chemical Abstracts, Volume 100, 1984 (Columbus, OH), E.C. Taylor et al., 'Synthesis and biological activity of 5-deaza folic acid and 5-deazaminopterin,' abstract no 68665j, Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin. Aspects, 7th 1982 (Pub. 1983), 115-19 (Eng.).	1-14, 20

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A

Chemical Abstracts, Volume 101, 1984
(Columbus, OH), S.R. Stone et al., Inhibition of dihydrotolate reductase from bacterial and vertebrate sources by folate, aminopterin, methotrexate and their 5-deaza analogs, abstract no. 19600w, Biochem. Pharmacol. 1984, 33(2), 175-9 (Eng.).

1-14, 20

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹⁰

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ¹¹

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the International application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.